These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

356 related items for PubMed ID: 19744284

  • 21. Cytomegalovirus incidence between everolimus versus mycophenolate in de novo renal transplants: pooled analysis of three clinical trials.
    Brennan DC, Legendre C, Patel D, Mange K, Wiland A, McCague K, Shihab FS.
    Am J Transplant; 2011 Nov; 11(11):2453-62. PubMed ID: 21812923
    [Abstract] [Full Text] [Related]

  • 22. Tacrolimus plus mycophenolate mofetil vs. cyclosporine plus everolimus in deceased donor kidney transplant recipients: three-yr results of a single-center prospective clinical trial.
    Favi E, Spagnoletti G, Salerno MP, Pedroso JA, Romagnoli J, Citterio F.
    Clin Transplant; 2013 Nov; 27(4):E359-67. PubMed ID: 23710603
    [Abstract] [Full Text] [Related]

  • 23. The survival of heart transplant recipients using cyclosporine and everolimus is not inferior to that using cyclosporine and mycophenolate.
    Wang SS, Chou NK, Chi NH, Huang SC, Wu IH, Wang CH, Yu HY, Chen YS, Tsao CI, Ko WJ, Shun CT.
    Transplant Proc; 2010 Apr; 42(3):938-9. PubMed ID: 20430209
    [Abstract] [Full Text] [Related]

  • 24. Observational study with everolimus (Certican) in combination with low-dose cyclosporine in de novo heart transplant recipients.
    Lehmkuhl HB, Mai D, Dandel M, Knosalla C, Hiemann NE, Grauhan O, Huebler M, Pasic M, Weng Y, Meyer R, Rothenburger M, Hummel M, Hetzer R.
    J Heart Lung Transplant; 2007 Jul; 26(7):700-4. PubMed ID: 17613400
    [Abstract] [Full Text] [Related]

  • 25. Successful conversion to everolimus after cytomegalovirus infection in a heart transplant recipient.
    Imamura T, Shiga T, Kinugawa K, Kato N, Endo M, Inaba T, Maki H, Hatano M, Yao A, Hirata Y, Nagai R.
    Int Heart J; 2012 Jul; 53(3):199-201. PubMed ID: 22790690
    [Abstract] [Full Text] [Related]

  • 26. Use of everolimus in de novo renal recipients: initial experience in the Greek population.
    Papanikolaou V, Vrochides D, Margari P, Imvrios G, Papagiannis A, Giakoustidis D, Fouzas I, Antoniadis N, Ouzounidis N, Ntinas A, Vergoulas G, Miserlis G, Solonaki F, Takoudas D.
    Transplant Proc; 2008 Nov; 40(9):3166-9. PubMed ID: 19010223
    [Abstract] [Full Text] [Related]

  • 27. Tacrolimus with mycophenolate mofetil or sirolimus compared with calcineurin inhibitor-free immunosuppression (sirolimus/mycophenolate mofetil) after heart transplantation: 5-year results.
    Kaczmarek I, Zaruba MM, Beiras-Fernandez A, Reimann R, Nickel T, Grinninger C, Sadoni S, Hagl C, Meiser B.
    J Heart Lung Transplant; 2013 Mar; 32(3):277-84. PubMed ID: 23415313
    [Abstract] [Full Text] [Related]

  • 28. Optimizing the immunosuppressive regimen in heart transplantation.
    Eisen H, Ross H.
    J Heart Lung Transplant; 2004 May; 23(5 Suppl):S207-13. PubMed ID: 15093807
    [Abstract] [Full Text] [Related]

  • 29. Reduced Incidence of Cytomegalovirus Infection in Kidney Transplant Recipients Receiving Everolimus and Reduced Tacrolimus Doses.
    Tedesco-Silva H, Felipe C, Ferreira A, Cristelli M, Oliveira N, Sandes-Freitas T, Aguiar W, Campos E, Gerbase-DeLima M, Franco M, Medina-Pestana J.
    Am J Transplant; 2015 Oct; 15(10):2655-64. PubMed ID: 25988935
    [Abstract] [Full Text] [Related]

  • 30. Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial.
    Budde K, Becker T, Arns W, Sommerer C, Reinke P, Eisenberger U, Kramer S, Fischer W, Gschaidmeier H, Pietruck F, ZEUS Study Investigators.
    Lancet; 2011 Mar 05; 377(9768):837-47. PubMed ID: 21334736
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Does mycophenolate mofetil increase the incidence of cytomegalovirus disease compared with azathioprine after cadaveric kidney transplantation?
    Basic-Jukic N, Kes P, Bubic-Filipi LJ, Puretic Z, Brunetta B, Pasini J.
    Transplant Proc; 2005 Mar 05; 37(2):850-1. PubMed ID: 15848553
    [Abstract] [Full Text] [Related]

  • 33. A Head-to-head Comparison of De Novo Sirolimus or Everolimus Plus Reduced-dose Tacrolimus in Kidney Transplant Recipients: A Prospective and Randomized Trial.
    Toniato de Rezende Freschi J, Cristelli MP, Viana LA, Ficher KN, Nakamura MR, Proença H, Dreige YC, de Marco R, de Lima MG, Foresto RD, Aguiar WF, Medina-Pestana J, Tedesco-Silva H.
    Transplantation; 2024 Jan 01; 108(1):261-275. PubMed ID: 37525373
    [Abstract] [Full Text] [Related]

  • 34. Kidney transplantation with sirolimus and mycophenolate mofetil-based immunosuppression: 5-year results of a randomized prospective trial compared to calcineurin inhibitor drugs.
    Flechner SM, Goldfarb D, Solez K, Modlin CS, Mastroianni B, Savas K, Babineau D, Kurian S, Salomon D, Novick AC, Cook DJ.
    Transplantation; 2007 Apr 15; 83(7):883-92. PubMed ID: 17460558
    [Abstract] [Full Text] [Related]

  • 35. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
    Anil Kumar MS, Irfan Saeed M, Ranganna K, Malat G, Sustento-Reodica N, Kumar AM, Meyers WC.
    Transpl Immunol; 2008 Nov 15; 20(1-2):32-42. PubMed ID: 18773960
    [Abstract] [Full Text] [Related]

  • 36. Economic evaluation of everolimus and mycophenolate mofetil versus azathioprine in de novo heart transplantation.
    Annemans L, Lemkuhl H, Tenderich G, Schulz U, Yang XL, Ricci JF, Hetzer R.
    Transplant Proc; 2007 Dec 15; 39(10):3306-12. PubMed ID: 18089377
    [Abstract] [Full Text] [Related]

  • 37. Safety of Everolimus With Reduced Calcineurin Inhibitor Exposure in De Novo Kidney Transplants: An Analysis From the Randomized TRANSFORM Study.
    Tedesco-Silva H, Pascual J, Viklicky O, Basic-Jukic N, Cassuto E, Kim DY, Cruzado JM, Sommerer C, Adel Bakr M, Garcia VD, Uyen HD, Russ G, Soo Kim M, Kuypers D, Buchler M, Citterio F, Hernandez Gutierrez MP, Bernhardt P, Chadban S, TRANSFORM Investigators.
    Transplantation; 2019 Sep 15; 103(9):1953-1963. PubMed ID: 30801548
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Is cytomegalovirus infection related to mycophenolate mofetil after kidney transplantation? A case-control study.
    Sarmiento JM, Munn SR, Paya CV, Velosa JA, Nguyen JH.
    Clin Transplant; 1998 Oct 15; 12(5):371-4. PubMed ID: 9787943
    [Abstract] [Full Text] [Related]

  • 40. Cytomegalovirus disease in de novo kidney-transplant recipients: comparison of everolimus-based immunosuppression without prophylaxis with mycophenolic acid-based immunosuppression with prophylaxis.
    Manière L, Noble J, Terrec F, Bennani HN, Chevallier E, Janbon B, Germi R, Bugnazet M, Imerzoukene F, Malvezzi P, Rostaing L, Jouve T.
    Int Urol Nephrol; 2021 Mar 15; 53(3):591-600. PubMed ID: 33058036
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.